Author:
Whittaker S,Marais R,Zhu A X
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference165 articles.
1. Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T et al. (2008). Final results from a phase II (PHII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). ASCO Gastrointestinal Cancers Symposium. Orlando, FL.
2. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. (2006). Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–4300.
3. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM . (2003a). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478.
4. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB et al. (2003b). Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with ‘standard of care’ therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 101–1021.
5. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ et al. (2006). Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5: 995–1006.
Cited by
734 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献